Get the Stockscreener App
36.28
5.64%
-2.17
Edgewise Therapeutics Inc stock is traded at $36.28, with a volume of 810.11K.
It is down -5.64% in the last 24 hours and down -18.29% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$38.45
Open:
$38.17
24h Volume:
810.11K
Relative Volume:
0.58
Market Cap:
$3.94B
Revenue:
Net Income/Loss:
$-176.01M
P/E Ratio:
-21.84
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
-9.35%
1M Performance:
-18.29%
6M Performance:
+7.21%
1Y Performance:
+146.63%
1-Day Range:
$36.08
$38.35
1-Week Range:
$36.08
$41.05
52-Week Range:
$14.25
$48.51
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
36.28 | 3.94B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-26 | Initiated | Oppenheimer | Outperform |
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Australia
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
A quarterly stock award gives director Fox 308 shares of Edgewise Therapeutics (EWTX). - stocktitan.net
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise Therapeutics Jumps As EDG-7500 Data Fuels Bullish Target Hike - StocksToTrade
Edgewise Therapeutics Stock Jumps As JPMorgan Hikes Target - timothysykes.com
Edgewise Therapeutics Stock Rises as JPMorgan Lifts Price Target - timothysykes.com
Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Four new employees receive stock awards from Edgewise - Stock Titan
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59 - Moomoo
The Technical Signals Behind (EWTX) That Institutions Follow - Stock Traders Daily
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 - PR Newswire
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Eastern Progress
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
EWTX Maintains Overweight Rating -- Price Target Raised to $60 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
Edgewise (EWTX) Results and Estimates: The Available Earnings Metric Delivers a Miss in the Available Record; Price Reaction: The Stock Ends Up 0.16% in Latest TradingConsensus Miss Rate - vinanet.vn
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics (EWTX) corrects CFO option grant price - Stock Titan
Edgewise Therapeutics (EWTX) corrects CMO’s 65K option grant price - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - MarketBeat
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - MarketBeat
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich - Sahm
Edgewise Therapeutics (EWTX) Gains 2.29% to $44.17, Maintains Upside MomentumStock Surge Alerts - vinanet.vn
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock - Investing.com
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Canada
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com Nigeria
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com Canada
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com Canada
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock By Investing.com - Investing.com Canada
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock By Investing.com - Investing.com India
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JOANNE DONOVAN | Officer |
Aug 13 '26 |
Proposed Sale |
43.56 |
2,919 |
127,152 |
0 |
| Donovan Joanne M. | CMO |
Aug 13 '26 |
Sale |
43.41 |
2,919 |
126,704 |
8,625 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Sale |
43.82 |
5,016 |
219,823 |
17,697 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
13,281 |
0 |
36,926 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Sale |
43.81 |
5,100 |
223,424 |
31,826 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Option Exercise |
0.00 |
39,844 |
0 |
70,459 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Sale |
43.68 |
17,971 |
785,042 |
52,488 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
12,812 |
0 |
37,367 |
| Donovan Joanne M. | CMO |
Aug 12 '26 |
Sale |
43.85 |
6,522 |
286,000 |
11,544 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Sale |
43.73 |
5,901 |
258,042 |
31,466 |
3.45%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):